ClinicalTrials.gg
RecruitingNCT07273994PERIVERSION-2Updated Dec 10, 2025

Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation

A Phase 4 interventional study of Amiodarone Hydrochloride 200 MG and Amiodarone Hydrochloride 100 MG in Persistent Atrial Fibrillation, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing amiodarone in Atrial Fibrillation — 12 open to participants now, 12 under way, 3 of them phase 3. Amiodarone · Atrial Fibrillation.

Planned enrollment
11th of 46
312 · median 124
Started
2025
the only one that year
Phase 4
20 of 46
5 open now
Primary completion
2027-12
later than 6 of 11 live
Registered
43rd of 46
by date

Among the 46 studies testing amiodarone in Atrial Fibrillation, this one is the 11th largest by planned enrollment, is the only one that started in 2025, is one of 20 in phase 4, reaches primary completion later than 6 of the 11 other live ones, and was the 43rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

12 of the 46 studies testing amiodarone in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About amiodarone

Amiodarone: first FDA approval 1985 (CORDARONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing amiodarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

---

The goal of this clinical trial is to learn if reduced doses of amiodarone can treat atrial fibrillation (AF) effectively while minimizing toxic side effects in patients with persistent AF after electrical cardioversion. The main questions it aims to answer are:

  • Can a reduced dose of amiodarone (100 mg/day) maintain sinus rhythm as effectively as the standard dose (200 mg/day) 12 months post electrical cardioversion?
  • What are the adverse effects of the standard and reduced doses of amiodarone during 12 months post electrical cardioversion?
  • How do genetic polymorphisms affect the efficacy and safety of amiodarone?
  • How do amiodarone plasma levels correlate with the maintenance of sinus rhythm and genetic polymorphisms?

Researchers will compare the standard dose (200 mg/day) to the reduced dose (100 mg/day) to see if the reduced dose offers a better balance between efficacy and safety.

Participants will:

  • Be treated with full dose amiodarone (200 mg/day) during the first month after electrical cardioversion.
  • Be randomized to either continue with the full dose (200 mg/day) or switch to the reduced dose (100 mg/day).

The study is a multicenter, randomized clinical trial involving 312 patients with persistent AF after successful electrical cardioversion. Participants will be followed for 12-18 months to monitor the recurrence of AF and adverse effects.

03

Conditions studied

  • Persistent Atrial Fibrillation

Browse trials for

Keywords

  • Atrial fibrillation
  • Electrical cardioversion
  • Amiodarone
  • Pharmacogenetics
  • Adverse effects
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 18 years
  2. Documented persistent atrial fibrillation (≥ 7 days in duration)
  3. Electively referred for Electrical Cardioversion
  4. Signed .

Exclusion criteria

Exclusion Criteria

  1. Urgent electrical cardioversion
  2. Atrial fibrillation post-cardiac surgery
  3. Previous myocardial infarction
  4. (NYHA) Class IV heart failure
  5. (LVEF) \<45%
  6. Significant left ventricular hypertrophy (wall thickness ≥ 15mm)
  7. Hyperthyroidism or hypothyroidism
  8. Known hepatobiliary disease (acute hepatitis, cirrhosis...) or /AST > 3 x (ULN)
  9. Allergy, intolerance, or known to study medications
  10. Women of unwilling to use measures and breastfeeding women.
  11. Participation in another clinical trial involving drugs
  12. less than 12 months
  13. Rheumatic mitral stenosis of any degree or severe mitral or aortic valve dysfunction.
  14. Patients with to amiodarone, such as uncontrolled thyroid dysfunction, severe sinus bradycardia, second- or third-degree AV block without a pacemaker, and a history of amiodarone-induced pulmonary toxicity.
  15. Patients in whom chronic amiodarone treatment previously failed to maintain sinus rhythm
  16. Patients with abnormal baseline (>450 ms in males and >470 in females) or abnormal that precludes QTc assessment
  17. Patients requiring concomitant medications that have a higher risk of QTc prolongation.
  18. Patient do not have a smart mobile phone or do not know how to use it adequately.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (estimated)

Study arms

  • Active comparator
    Amiodarone full doses

    Patients will receive amiodarone full doses (200 mg/day) (Usual dose)

    Drug: Amiodarone Hydrochloride 200 MG

  • Experimental
    Amiodarone reduced doses

    Patients will receive amiodarone reduced doses (100 mg/day)

    Drug: Amiodarone Hydrochloride 100 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Maintenance of sinus rhythm

    Number of patients mantaining sinus rhythm 12 months post electrical cardioversion

    Time frame: 12 months follow-up

Secondary outcomes

  1. Adverse effects

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 12 months follow-up

  2. Polymorphisms

    Association of the different assessed polymorphisms with the primary and first secondary outcome

    Time frame: 12 months follow-up

  3. Plasma levels

    Correlation of amiodarone plasma levels during follow-up with the maintenance of sinus rhythm

    Time frame: 12 months follow-up

Other outcomes

  1. Plasma levels - polymorphisms

    Correlation of amiodarone plasma levels with polymorphisms

    Time frame: 12 month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 25 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Dec 10, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07273994
Collaborators
Instituto de Salud Carlos III
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Nov 1, 2025
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Dec 10, 2025

Study contacts

Jose M Guerra, MD, PhD
Contact
jguerra@santpau.cat
+34 935565945

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amiodarone

Start the discussion